



| | MESO-PRIME | MIST | | | | | | |
|---|---|---|--|--|--|---|---|--|
| Trial title | Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in patients with Malignant Pleural Mesothelioma | A stratified multi-arm phase IIa clinical trial to enable accelerated evaluation of targeted therapies for relapsed malignant mesothelioma | | | | | | |
| Type | CTIMP | Second line and beyond | | | | | | |
| Treatment/study focus | Malignant Pleural Mesothelioma (MPM) | Molecular Pre-screening, Drug Treatment, Genomic Profiling | | | | | | |
| Phase | Phase I | Phase IIa | | | | | | |
| Sponsor | Royal Marsden NHS Foundation Trust | University of Leicester | | | | | | |
| Drug companies involved | Funding provided by MSD | Clovix Oncology, Inc. Eli Lilly and Company GSK Merck Sharp & Dohme Corp. (MSD) BerGenBio ASA Roche Pharma AG | | | | | | |
| Principal investigator | Chief Investigator: Dr Fiona McDonald (Royal Marsden) Dr Fiona McDonald = Royal Marsden PI Dr Nicola Steele = Beatson PI | Principal Investigator: Professor Anne Thomas Scientific Lead: Professor Dean Fennell | | | | | | |
| Contact | mesoprime.trial@rmh.nhs.uk | MIST Management Team: MISTmailbox@leicester.ac.uk | | | | | | |
| Description | This is a non-randomised open-label phase I trial of pembrolizumab given in combination with SBRT to part of a pleural-based lesion in patients with unresectable MPM. This study will recruit up to 18 patients whose MPM has progressed beyond first-line of palliative chemotherapy, with a platinum-based doublet, and now requires further palliative systemic treatment, or have declined first-line palliative chemotherapy, however must have been considered suitable for a platinum doublet chemotherapy | <p>Stage 1 - molecular pre-screening: The MIST Master protocol describes the identification of patients, biomarker testing and analysis. Patients with relapsed mesothelioma will be offered to consent for molecular panel testing of their diagnostic tumour block for predictive biomarkers. The results of this assessment will be used to classify patients into one of several possible molecularly defined treatment arms. Patients will therefore be offered a specific study treatment determined by their molecular profile. Patients, who exhibit positive testing in more than one biomarker, will potentially be eligible to subsequently be treated on a different treatment protocol upon disease progression or treatment failure.</p> <p>Stage 2 - Treatment: The MIST treatment protocol will be specific to the treatment allocated to the patient - based on the results of their biomarker testing in stage 1. Specific agent(s) will be detailed separately in each of the separate treatment protocols.</p> <p>Stage 3 - Molecular Profiling : In order to understand the genomic basis of drug response in the MIST trial, archival tumour tissue from all patients enrolled will be interrogated using molecular inversion probe- based microarray analysis of the somatic copy number aberrations. Optional re-biopsy of patients who progress on treatment, followed confirmed radiological response, will be offered, to investigate genomic interrogation of tumours at the time of acquired resistance. For arms 3 and 4, immune checkpoint, transcriptomic and gut microbiome correlative studies are planned</p> <p>For MIST 5: For Dostarlimab, 1 cycle of treatment constitutes 21 days of treatment for cycles 1 – 4, and 42 days from cycle 5 onwards. For Niraparib, 1 cycle constitutes 21 days of treatment. Both will take a total of 24 weeks.</p> <p>If patients are benefitting after 8 cycles of study treatment have been received they may be able to continue receiving treatment either in combination or as a monotherapy.</p> | | | | | | |
| Randomised? Y/N | No | No | | | | | | |
| Treatment Schedule | Part A – Initial safety cohort Patients will receive an initial dose of pembrolizumab in week 1 dosed at 200 mg. They will then receive SBRT dosed at 30 Gy in 3 fractions (#) alternate days in week 3. Treatment with pembrolizumab will be continued dosed at 200 mg given every 3 weeks. Part B – Expansion cohort. An additional 12 patients will be recruited for this cohort. Patients will receive an initial dose of pembrolizumab at 200 mg in week 1. This will be followed in by SBRT dosed at 30 Gy in 3 fractions (#) alternate days in week 3. Treatment with pembrolizumab will be continued dosed at 200 mg given every 3 weeks. | <p>A course of treatment will be defined as follows: (For MIST1 & MIST2: 1 cycle of treatment constitutes 28 days of treatment therefore all 6 cycles/a course will take a total of 24 weeks). If patients are benefitting after all 6 cycles of study treatment have been received may be able to continue receiving treatment.</p> <p>(For MIST3 & MIST4: 1 cycle of treatment constitutes 21 days of therapy therefore all 8 cycles/a course will take a total of 24 weeks). If patients are benefitting after all 8 cycles of study treatment have been received may be able to continue receiving treatment either in combination or as a monotherapy.</p> | | | | | | |
| Treatment route | Intravenous Pembrolizumab and External Beam Stereotactic Body Radiotherapy (SBRT) | Oral tablet and IV depending on treatment arm – please see below. | | | | | | |
| Drugs used | Pembrolizumab | <p>MIST5 Dostarlimab & Niraparib. <i>Recruiting</i> No specific biomarker requirement – platinum sensitivity (response or stable disease, but not progression as their best response to first line or re-challenge platinum doublet therapy): Dostarlimab 500mg IV infusion on Day 1 of each 21 day cycle for 4 cycles, followed by 1000mg on Day 1 of each 42 day cycle from cycle 5 onwards. Niraparib orally once daily for each 21 day cycle, with starting dose of 300mg or 200mg</p> <p>MIST3 Pembrolizumab & Bemcentinib. <i>Fully recruited</i> No specific biomarker requirement: Pembrolizumab 200mg IV infusion on Day 1 only; Bemcentinib loading dose of 400mg on days 1-3, on day 4 on-wards 200mg daily every 21-days.</p> <table border="1"> <thead> <tr> <th>MIST1 Rucaparib. <i>Fully recruited.</i></th> <th>MIST2 Abemaciclib. <i>Fully recruited.</i></th> <th>MIST4 Atezolizumab & Bevacizumab. <i>Fully Recruited</i></th> </tr> </thead> <tbody> <tr> <td>BRCA1/BAP1 negative mesothelioma; 600mg twice daily (BD) every 28 days.</td> <td>p16INK4A negative mesothelioma; 200mg orally twice daily every 28 days.</td> <td>No specific biomarker requirement: Atezolizumab 1200 milligrams via intravenous infusion; Bevacizumab 15 milligrams per kilogram via IV infusion both on Days 1 every 21-days.</td> </tr> </tbody> </table> | MIST1 Rucaparib. <i>Fully recruited.</i> | MIST2 Abemaciclib. <i>Fully recruited.</i> | MIST4 Atezolizumab & Bevacizumab. <i>Fully Recruited</i> | BRCA1/BAP1 negative mesothelioma; 600mg twice daily (BD) every 28 days. | p16INK4A negative mesothelioma; 200mg orally twice daily every 28 days. | No specific biomarker requirement: Atezolizumab 1200 milligrams via intravenous infusion; Bevacizumab 15 milligrams per kilogram via IV infusion both on Days 1 every 21-days. |
| MIST1 Rucaparib. <i>Fully recruited.</i> | MIST2 Abemaciclib. <i>Fully recruited.</i> | MIST4 Atezolizumab & Bevacizumab. <i>Fully Recruited</i> | | | | | | |
| BRCA1/BAP1 negative mesothelioma; 600mg twice daily (BD) every 28 days. | p16INK4A negative mesothelioma; 200mg orally twice daily every 28 days. | No specific biomarker requirement: Atezolizumab 1200 milligrams via intravenous infusion; Bevacizumab 15 milligrams per kilogram via IV infusion both on Days 1 every 21-days. | | | | | | |
| Entry criteria | <ol style="list-style-type: none"> Patients should be ≥18 years old on the day of signing the informed consent. Patients must have a histological or cytological diagnosis of MPM. Patients should have non-radically treatable MPM (i.e. not being considered for extrapleural pneumonectomy or pleurectomy and decortication). Patients must have measurable disease as assessed by mRECIST. Patients must have had disease progression or be intolerant of standard first-line palliative chemotherapy for MPM. Patients who have declined first-line palliative chemotherapy must have been suitable for platinum-doublet combination chemotherapy. Patient should have an ECOG performance status 0-1 Patients should be able to tolerate a course of SBRT as assessed by the investigator. Patients should have pleural-based disease, away from critical structures, suitable for treatment to part of lesion with SBRT. Patients must have adequate organ function including MRC dyspnoea score <3 and adequate baseline lung function tests, with an FEV1 >0.8L or >30% of predicted and a TLC0 >30% Demonstrate adequate organ function as detailed in Table 2 (based on bloods within 10 days of C1D1). Have provided tissue from an archival tissue sample or newly obtained tissue sample. Female patient of childbearing potential should have a negative serum pregnancy within 72 hours prior to receiving the first dose of study medication (C1D1). Female patients of childbearing potential should be willing to use highly effective methods of contraception for the course of the study through 120 days after the last dose of study medication. Male patients should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy. Be willing to provide informed consent for the trial. | <ol style="list-style-type: none"> Histologically confirmed MM with an available biopsy for research purposes Male or female patients aged ≥18 years. Expected survival of ≥12 weeks or greater ECOG PS 0-1 CT scan chest, abdomen (and pelvis if applicable) confirming disease progression. Patients must have received at least one prior line of therapy to include a platinum doublet first-line chemotherapy (within or outside of another clinical trial) Willing to consent for molecular screening of archived tumour block (PIS1 & CF1) | | | | | | |
| Exclusion criteria | <ol style="list-style-type: none"> Patients who have taken any investigational medicinal product or have used an investigational device within 4 weeks of the first dose of pembrolizumab. Patients are allowed to participate in additional observational studies. Patients who have received prior chemotherapy, targeted small molecule therapy or radiotherapy within 4 weeks prior to the first dose of pembrolizumab. Patients with a diagnosis of immunodeficiency or be receiving systemic steroid therapy (>7.5 mg of prednisone / >1 mg of dexamethasone or their equivalent dose) or any other form of immunosuppressive therapy within 7 days prior to the first dose. Patients with evidence of active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents or an autoimmune disease that is currently quiescent off any treatment, but deemed at risk of a significant flare if treated on this protocol. Patients who have received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways). Patients with evidence of active central nervous system (CNS) metastases and/or carcinomatous meningitis. Patients with previously treated brain metastases may participate provided the brain metastases are stable and there is no evidence of new or enlarging brain metastases. Patients who have had previous radiotherapy to the thorax or other neighbouring region that would preclude the safe administration of SBRT for MPM. Patients with evidence of interstitial lung disease, or history of pneumonitis (including non-infectious pneumonitis) that required steroids, or current pneumonitis (including non-infectious pneumonitis). Patients with evidence of additional malignancy that is progressing or requires active treatment. Patients with a history or current evidence of any condition, therapy, or laboratory abnormality that might confound trial results, interfere with the patient's participation or is not in the best interest of the patient. Patients with psychiatric or substance abuse disorders that would interfere with patients participation. Patients who are pregnant / breastfeeding or expecting to conceive within the duration of the trial, starting with the screening visit through 120 days after the last dose. Patients with a history of HIV, HIV 1/2 antibodies, Hepatitis B or Hepatitis C. Patients with any active infection requiring systemic treatment Patients who have received a live vaccine within 30 days prior to the first dose of trial treatment. Patients with known hypersensitivity to the active substance pembrolizumab or to any of the excipients listed in the IB. | <ol style="list-style-type: none"> Patients with a diagnosis of a second malignancy except prostate or cervical cancer in remission, patients with a diagnosis of basal cell carcinoma of the skin or superficial bladder cancer. Uncontrolled CNS disease. Asymptomatic brain metastases are allowed if previously treated with radiotherapy >28 days prior to starting the investigational agent. New York Heart Association Class II or greater congestive heart failure. Patients with severe hepatic insufficiency or severe renal impairment. Patients requiring long term oxygen therapy. Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial. | | | | | | |
| Performance status criteria | Patient should have an ECOG performance status 0-1 | 0-1 | | | | | | |
| Participants required | 18 | 200 – pre-screening, 26 in to each treatment arm | | | | | | |
| No. of participants to date | 4 | MIST Master : 155 patients recruited, MIST 1: Complete, MIST 2: Complete, MIST 3: Complete, MIST 4: Complete, MIST 5: 9 patients recruited | | | | | | |
| Centres opening & recruiting | Beatson West of Scotland Cancer Centre - Open to recruitment Royal Marsden NHS Foundation Trust - Open to recruitment | <p>Currently open and recruiting: University Hospitals of Leicester NHS Trust</p> <p>In setup for MIST 5: Wythenshawe Northern Centre for Cancer Care, Newcastle Southampton General Hospital</p> | | | | | | |
| Where can patients get more information? | https://clinicaltrials.gov/ct2/show/NCT04166734?term=NCT04166734&draw=2&rank=1 or mesoprime.trial@rmh.nhs.uk | https://clinicaltrials.gov/ct2/show/NCT03654833 | | | | | | |
| Where can healthcare professionals get more information? | https://clinicaltrials.gov/ct2/show/NCT04166734?term=NCT04166734&draw=2&rank=1 or mesoprime.trial@rmh.nhs.uk | MISTmailbox@le.ac.uk | | | | | | |



| | MITOPE | BEAT-Meso - now closed | SYSTEMS-2 | ASSESS-MESO |
|---|--|---|--|--|
| Trial title | A Translational Phase 1/2 Dose-Escalation and Expansion Study to Determine Safety, Tolerability, and Recommended Phase 2 Dose of RSO-021 in Patients with Malignant Pleural Effusion due to Advanced/Metastatic Solid Tumors including Mesothelioma. (MITOPE) | ETOP 13-8 Bevacizumab and atezolizumab in malignant pleural mesothelioma. A multicentre randomised phase III trial comparing atezolizumab plus bevacizumab and standard chemotherapy versus bevacizumab and standard chemotherapy as first-line treatment for advanced malignant pleural mesothelioma | SYSTEMS-2: A Randomised Phase II trial of standard versus dose escalated radiotherapy in the treatment of pain in malignant pleural mesothelioma | A prospective observational cohort study collecting data on demographics, symptoms and biomarkers in people with mesothelioma that will provide a resource for future trials |
| Type | Second line and beyond | First line | Radiotherapy | Non-interventional, observational |
| Treatment/study focus | Malignant Pleural Effusion, Malignant Pleural Mesothelioma, Metastatic Solid Tumors | Drug treatment / all histological subtypes of malignant pleural mesothelioma | Radiotherapy for pain control | To collect information about mesothelioma and the people who develop it, their symptoms, and how things change over time, whilst also screening participants for clinical trial participation. |
| Phase | Phase I/II | Phase III | Phase II | N/A |
| Sponsor | RS Oncology LLC, Cambridge MA, USA | European Thoracic Oncology Platform (ETOP) | Sponsor: Beatson Cancer Charity and June Hancock Mesothelioma Research Fund Academic institution: University of Glasgow | North Bristol NHS Trust |
| Drug companies involved | RS Oncology LLC, Cambridge MA, USA | F. Hoffman-La Roche Ltd. | None | None |
| Principal investigator | Chief Investigator: Dr. James Spicer (Guy's), Dr. Alastair Greystoke (Newcastle), Dr. Fiona Thistlethwaite (The Christie), Dr. Simon Lord (Oxford), Dr. Dean Fennell (Leicester), and Dr. Peter Szlosarek (St. Bart's) | Prof. Sanjay Popat (Trial Co-Chair) | Professor Anthony Chalmers | Dr Anna Bibby |
| Contact | MITOPE management team at MITOPE@rsoncology.com | Maria.Piga@rmh.nhs.uk (Lead Clinical Research Nurse) | Dr Miranda Ashton (Clinical Oncology Registrar) Miranda.ashton@ggc.scot.nhs.uk | Anna.bibby@bristol.ac.uk (PI) Jenny Symonidis (Study coordinator) |
| Description | This is an open label, non-randomized translational phase 1/2 dose- escalation and expansion study to determine the safety, tolerability, maximum tolerated dose and/or recommended phase 2 dose, pharmacokinetics and pharmacodynamics of RSO- 021 after intrapleural administration in patients with MPE. Patients must also have received and progressed on at least 1 standard line of treatment. The study will also evaluate antitumor activity of RSO-021 in two separate expansion cohorts; (1) in patients with MPE (non-mesothelioma) and (2) in patients with MPE from mesothelioma (up to 42 patients total for both cohorts). | This is a randomised, open-label, multicentre phase III trial. Patients will be randomly assigned (1:1) to one of two treatment arms: 1) control arm: standard chemotherapy (carboplatin and pemetrexed) and bevacizumab, or 2) treatment arm: standard chemotherapy (carboplatin and pemetrexed) and bevacizumab plus atezolizumab. The efficacy (whether the treatment works), safety and tolerability (side effects of treatment) of atezolizumab plus bevacizumab in combination with standard chemotherapy versus bevacizumab in combination with standard chemotherapy will be investigated in the first-line treatment of advanced malignant pleural mesothelioma | A randomised, multicentre trial of radiotherapy dose escalation for pain control in malignant pleural mesothelioma. Patients will be randomised to receive either standard dose radiotherapy (20Gy in 5 treatments) over 1 week, or a higher dose (36Gy in 6 treatments) over 2 weeks. The aim of the trial is to assess whether the higher dose of radiotherapy is more effective for pain 5 weeks after the start of treatment. Methods of radiotherapy delivery which limit the dose received by normal tissues will be used to minimise side effects. | We want to learn more about mesothelioma, specifically whether there are any patient characteristics, factors relating to the tumour, or blood tests that will allow us to predict which patients might respond better to chemotherapy or other treatments, or to live longer. We also want to know about people's symptoms and how these may change over time. ASSESS-meso is a 'real-life' study that will collect information from patients at their routine clinic appointments. This information includes symptom scores, imaging such as x-rays, ultrasounds and CT scans, and blood tests and collection of pleural fluid (if present). We will also screen participants to see if there are any clinical trials they may be eligible for. If you are not having regular appointments in hospital, there is an option to undergo telephone study assessments. |
| Randomised? Y/N | No | Yes | Yes | No |
| Treatment Schedule | RSO-021 will be administered once-a-week via an indwelling IP catheter, until disease progression, unacceptable toxicity, withdrawal of consent or study termination. Prior to each dose administration, the patient will have their pleural effusion drained to dryness, as per standard of care (SOC). Phase 1 - Initial dose escalation cohort (max 30 patients) Patients will receive either 90, 180, 270, 360, or 450 mg of RSO-021 as outlined above. Phase 2 - Expansion cohorts (max 42 patients, 21 patients per cohort) Patients will receive the RP2D, derived from the Phase 1 part of the trial as outlined above. | Treatment arm 1 (control): • 4-6 cycles of: standard chemotherapy (carboplatin + pemetrexed) plus bevacizumab followed by maintenance bevacizumab Treatment arm 2 (experimental): • 4-6 cycles of standard chemotherapy (carboplatin + pemetrexed) plus bevacizumab plus atezolizumab followed by maintenance bevacizumab plus atezolizumab <i>* Drugs will be given every 3 weeks until progression, refusal or unacceptable toxicity</i> | • Visit 1: Screening visit (up to 1 month before radiotherapy) • Visit 2: Baseline visit (up to 1 week before radiotherapy) • Visit 3: Final day of radiotherapy • Visit 4: Week 5 after the start of radiotherapy • Visit 5: Week 9 after the start of radiotherapy • Visit 6: Week 26 after the start of the radiotherapy | Study assessment visits will be co-ordinated with routine clinic appointments |
| Treatment route | Local intrapleural (IP) administration via an indwelling IP catheter | Intravenous | External beam radiotherapy | All participants will continue to receive treatment as usual whilst participating in this study. |
| Drugs used | RSO-021 first-in-human administration | Treatment arm 1 (control): carboplatin, pemetrexed, and bevacizumab Treatment arm 2 (experimental): carboplatin, pemetrexed, bevacizumab, and atezolizumab | No drugs used (radiotherapy trial) Treatment arm: 36Gy in 6 fractions delivered over 2 weeks Control arm: 20Gy in 5 fractions delivered over 1 week | All participants will continue to receive treatment as usual whilst participating in this study. |
| Entry criteria | 1. Male or female ≥ 18 years old. 2. ECOG performance status 0-1. 3. Dose escalation: histological diagnosis of MPE from any solid tumor. Dose expansions: histological diagnosis of MPE caused by non-mesothelioma solid tumor or mesothelioma. 4. For patients with MPE from any other solid tumors, the MPE must be considered the priority for symptom control as potentially life limiting (or quality of life limiting). 5. MPE other solid tumors: patients must have received at least 1 prior standard of care treatment regimen for advanced, unresectable malignancy, with documented progression per RECIST 1.1. MPE mesothelioma: patients must have received at least 1 prior standard of care treatment regimen for advanced, unresectable malignancy, with documented progression (revised mRECIST 1.1 for mesothelioma) and there is no approved life extending alternative available. 6. Resolution of all acute reversible toxic effects of prior therapy or surgical procedure to Grade ≤1 (except alopecia). 7. For dose escalation: tumor tissue (a minimum of 10 and up to 15 unstained slides), or paraffin block, ideally from the patient's most recent biopsy, should be provided prior to the first dose of study therapy if sufficient tissue is available. For dose expansion cohorts: fresh tumor biopsy must be obtained. a. Patients enrolled in the mesothelioma expansion phase will be requested to undergo a tumor biopsy during the screening period and after the third dose. b. Patients enrolled in the non-mesothelioma expansion phase will be requested to undergo a tumor biopsy during the screening period and after the third dose only if medically feasible. 8. Adequate organ function as defined by the following criteria: Absolute neutrophil count (ANC) ≥1500/mcL; Platelets ≥100 x10 ⁹ /L; Hemoglobin ≥9 g/dL; eGFR (CKD-EPI calculation) >30 mL/min/1.73m ² ; Serum total bilirubin ≤1.5 ULN or Direct bilirubin ≤ ULN for patients with total bilirubin >1.5 ULN; AST and ALT ≤2.5 ULN or ≤5 ULN if liver metastases; Albumin >25 g/L; INR ≤1.5 aPTT (if not on anticoagulants) <1.5 ULN (if not on anticoagulants) (if on anticoagulants, value must be within prophylactic range for condition under consideration) 9. If not postmenopausal or surgically sterile, patients must be willing to practice at least one of the following highly effective methods of birth control (defined as having a low failure rate, i.e., less than 1% per year) for at least a (partner's) menstrual cycle before and for 4 months after last study drug administration: a. True abstinence, when this is in line with the preferred and usual lifestyle of the patient, from sexual intercourse with a member of the opposite sex; b. Sexual intercourse with vasectomized male/sterilized female partner; c. Hormonal female contraceptive (oral, parenteral, intravaginal, implantable or transdermal) for at least 3 consecutive months prior to investigational product administration (when not clinically contraindicated as in breast, ovarian and endometrial cancers); d. Use of an intrauterine contraceptive device. 9. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures. | 1. Histologically confirmed advanced malignant pleural mesothelioma (all histological subtypes are eligible) 2. Not amenable for radical surgery based on local standards 3. Evaluable disease or measurable disease as assessed according to the modified response evaluation criteria for solid tumours for mesothelioma (mRECIST) v1.1 4. Availability of tumour tissue for translational research 5. Age ≥18 years 6. Performance Status 0-1 7. Life expectancy ≥3 months 8. Adequate haematological, renal and liver function 9. Completed baseline quality of life (QoL) questionnaire 10. Women of childbearing potential and sexually active men must agree to use highly effective contraception 11. Able to understand and give written informed consent and comply with trial procedures | 1. Malignant pleural mesothelioma (histological or MDT diagnosis) 2. Predicted life expectancy >12 weeks 3. CT scan within 8 weeks of starting radiotherapy 4. Worst pain score ≥ 4/10 after analgesia optimisation 5. Radiotherapy plan compatible with treatment arm (36Gy/6 fractions or 30Gy in 5 fractions) prior to randomisation | Any patient with mesothelioma, whose diagnosis has been confirmed at multidisciplinary team meeting, and who is willing (and able) to attend study follow up assessments. |
| Exclusion criteria | 1. Last dose of prior anti-cancer therapies: a. Systemic anti-cancer therapy within 3 weeks or 5 half-lives prior to study entry, whichever is shorter. b. Thoracic radiation therapy or significant surgery within 3 weeks prior to study entry. Localized palliative radiotherapy for pain control in non-target lesions is allowed during the screening period. c. Received an investigational product or been treated with an investigational device within 30 days prior to first drug administration or plans to participate in any other clinical trial while on this study. 2. Previous or concurrent malignancy that would prevent evaluation of the primary endpoint (e.g., relapsed/refractory hematological malignancy). 3. Patients whose extent of tumor or localizations would render intrapleural administration incomplete and/or ineffective. 4. Known hypersensitivity to the active ingredient or any excipient contained in the drug formulation. 5. History or clinical evidence of any surgical or medical condition which the investigator and/or medical monitor judges as likely to interfere with the results of the study or pose an additional risk in participating, e.g., rapidly progressive or uncontrolled disease involving a major organ system—vascular, cardiac, pulmonary, gastrointestinal, gynecologic, hematologic, neurologic, neoplastic, renal, endocrine, or an immunodeficiency, or clinically significant active psychiatric or abuse disorders. 6. Patients with active uncontrolled infection or known to be serologically positive for HIV, hepatitis B or hepatitis C infection. Investigators may test per their discretion. 7. Pregnant or breast-feeding patients. 8. Patients with symptomatic or unstable central nervous system (CNS) primary tumor or metastases and/or carcinomatous meningitis. Patients with documented treated CNS metastases stable off steroids may be enrolled at the discretion of the investigator. 9. Therapeutic oral anticoagulation for a thromboembolic event (prophylactic anticoagulation is allowed as long as patient can undergo catheter placement and biopsy). Low molecular weight heparin (LMWH) is allowed on condition that it is medically acceptable to interrupt LMWH therapy for all invasive procedures in Table 1. 10. Use of systemic corticosteroids to treat inflammatory or autoimmune symptoms within 15 days or other immunosuppressive drugs within 3 weeks prior to start of the study. Inhaled and topical corticosteroids are permitted. Up to 10 mg/day prednisone or equivalent is permitted. | 1. Prior treatment for malignant pleural mesothelioma 2. Treatment with systemic immune-stimulatory agents within 4 weeks or five half-lives of the drug prior to randomisation and during protocol treatment. 3. Treatment with systemic immunosuppressive medications within 2 weeks prior to randomisation and during protocol treatment. 4. Previous allogeneic tissue/solid organ transplant 5. Live vaccines within 4 weeks prior to first dose of protocol treatment 6. Inadequately controlled hypertension 7. Prior history of hypertensive crisis or hypertensive encephalopathy 8. Significant vascular disease within 6 months prior to randomisation 9. History of haemoptysis | 1. Anticancer therapy 4 weeks prior to study entry or 6 weeks after radiotherapy 2. Patients who have previously received palliative radiotherapy and where there is concern that the proposed treatment volume would overlap with the previously irradiated area. This does not include patients who have received superficial photon or electron therapy to drain sites 3. Coexisting lung tumours at the time of study entry | 1. Age <18 years old 2. Unable to give written informed consent 3. Declines ongoing hospital follow up |
| Performance status criteria | 0-1 | 0-1 | 0-2 | All |
| Participants required | Phase 1 up to 30 patients and Phase 2 up to 42 patients | 320 randomised patients in total | 112 | 700 |
| No. of participants to date | 0 | TBC | 104 | 262 |
| Centres opening & recruiting | Sites currently open: Leicester Sites in set up: The Christie, Manchester Guy's and St Thomas' Hospital Newcastle Oxford St. Bart's | Limited slots available on request in UK: Addenbrooke's Royal Marsden Hospital - Chelsea, Sutton Royal Cornwall Hospital (Truro) Guy's and St Thomas' Hospital Kent Oncology Centre (Maidstone) Plymouth Hospitals NHS Trust Clatterbridge Cancer Centre Weston Park Hospital (Sheffield) Wythenshawe Hospital. 45 centres in 8 European countries (Belgium, France, Italy, Portugal, Slovenia, Spain, Switzerland, United Kingdom) | Recruitment period has been extended until August 2022. Aberdeen Beatson, Glasgow Belfast City The Christie Churchill Hospital, Oxford Forth Valley Royal Hospital, Larbert Guy's and St Thomas', London Kent and Canterbury Hospital Leeds Maidstone New Cross Hospital, Wolverhampton Royal Shrewsbury Hospital Southend University Hospital, Essex The Royal Marsden University Hospital Southampton Western General, Edinburgh Weston Park, Sheffield | Sites currently open: Bath Hywel Dda Leicester Manchester NHS Greater Glasgow and Clyde North Bristol Northumbria Healthcare NHS Foundation Oxford Papworth Pennine Acute Hospitals NHS Trust (North Manchester) Plymouth Sherwood Forest Hospitals Foundation Trust South Tyneside Taunton University Hospitals of Derby and Burton NHS Foundation Trust Wales - Velindre Cancer Centre Sites in set up: Norfolk & Norwich Northern General Hospital, Sheffield Mid and South Essex NHS Foundation Trust Other interested sites: University Hospitals Morecambe Bay NHS Trust The Clatterbridge Cancer Centre NHS FT NHS Highland |
| Where can patients get more information? | clinicaltrials.gov and MITOPE@rsoncology.com | https://clinicaltrials.gov/ct2/show/study/NCT03762018 | Their local clinical oncologist miranda.ashton@ggc.scot.nhs.uk www.systems-2.co.uk | anna.bibby@bristol.ac.uk (PI) |
| Where can healthcare professionals get more information? | clinicaltrials.gov and MITOPE@rsoncology.com | Maria.Piga@rmh.nhs.uk (Lead Clinical Research Nurse) | laura.alexander@glasgow.ac.uk miranda.ashton@ggc.scot.nhs.uk www.systems-2.co.uk | anna.bibby@bristol.ac.uk |